Non-Invasive Biomarkers for Early Lung Cancer Detection

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Dec 11

PMID 36497263

Authors

Harman Saman

Afsheen Raza

Kalyani Patil

Shahab Uddin

Tatjana Crnogorac-Jurcevic

Affiliations

Soon will be listed here.

Abstract

Worldwide, lung cancer (LC) is the most common cause of cancer death, and any delay in the detection of new and relapsed disease serves as a major factor for a significant proportion of LC morbidity and mortality. Though invasive methods such as tissue biopsy are considered the gold standard for diagnosis and disease monitoring, they have several limitations. Therefore, there is an urgent need to identify and validate non-invasive biomarkers for the early diagnosis, prognosis, and treatment of lung cancer for improved patient management. Despite recent progress in the identification of non-invasive biomarkers, currently, there is a shortage of reliable and accessible biomarkers demonstrating high sensitivity and specificity for LC detection. In this review, we aim to cover the latest developments in the field, including the utility of biomarkers that are currently used in LC screening and diagnosis. We comment on their limitations and summarise the findings and developmental stages of potential molecular contenders such as microRNAs, circulating tumour DNA, and methylation markers. Furthermore, we summarise research challenges in the development of biomarkers used for screening purposes and the potential clinical applications of newly discovered biomarkers.

Citing Articles

PET radiomics-based lymphovascular invasion prediction in lung cancer using multiple segmentation and multi-machine learning algorithms.

Hosseini S, Hajianfar G, Ghaffarian P, Seyfi M, Hosseini E, Aval A Phys Eng Sci Med. 2024; 47(4):1613-1625.

PMID: 39225775 PMC: 11666702. DOI: 10.1007/s13246-024-01475-0.

AI Applied to Volatile Organic Compound (VOC) Profiles from Exhaled Breath Air for Early Detection of Lung Cancer.

Vinhas M, Leitao P, Raimundo B, Gil N, Vaz P, Luis-Ferreira F Cancers (Basel). 2024; 16(12).

PMID: 38927906 PMC: 11201396. DOI: 10.3390/cancers16122200.

The Early Diagnosis of Lung Cancer: Critical Gaps in the Discovery of Biomarkers.

Gasparri R, Sabalic A, Spaggiari L J Clin Med. 2023; 12(23).

PMID: 38068296 PMC: 10707119. DOI: 10.3390/jcm12237244.

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection.

Wiesel O, Sung S, Katz A, Leibowitz R, Bar J, Kamer I Biosensors (Basel). 2023; 13(6).

PMID: 37366992 PMC: 10296167. DOI: 10.3390/bios13060627.

Advances in Lung Cancer Therapy.

Galetta D Cancers (Basel). 2023; 15(10).

PMID: 37345008 PMC: 10216240. DOI: 10.3390/cancers15102671.

References

Sacher A, Komatsubara K, Oxnard G . Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review. J Thorac Oncol. 2017; 12(9):1344-1356. DOI: 10.1016/j.jtho.2017.05.022. View

Chen P, Cai L, Huffman K, Yang C, Kim J, Faubert B . Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Mol Cell. 2019; 76(5):838-851.e5. PMC: 6898782. DOI: 10.1016/j.molcel.2019.08.028. View

Ji X, Bosse Y, Landi M, Gui J, Xiao X, Qian D . Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun. 2018; 9(1):3221. PMC: 6089967. DOI: 10.1038/s41467-018-05074-y. View

Cassidy A, Myles J, van Tongeren M, Page R, Liloglou T, Duffy S . The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2007; 98(2):270-6. PMC: 2361453. DOI: 10.1038/sj.bjc.6604158. View

Belinsky S, Liechty K, Gentry F, Wolf H, Rogers J, Vu K . Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006; 66(6):3338-44. DOI: 10.1158/0008-5472.CAN-05-3408. View

Hoang G, Udupa S, Le A . Application of metabolomics technologies toward cancer prognosis and therapy. Int Rev Cell Mol Biol. 2019; 347:191-223. DOI: 10.1016/bs.ircmb.2019.07.003. View

Slavin T, Banks K, Chudova D, Oxnard G, Odegaard J, Nagy R . Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018; :JCO1800328. PMC: 6286162. DOI: 10.1200/JCO.18.00328. View

Alahmari S, Cherezov D, Goldgof D, Hall L, Gillies R, Schabath M . Delta Radiomics Improves Pulmonary Nodule Malignancy Prediction in Lung Cancer Screening. IEEE Access. 2019; 6:77796-77806. PMC: 6312194. DOI: 10.1109/ACCESS.2018.2884126. View

Levine B, Kroemer G . Biological Functions of Autophagy Genes: A Disease Perspective. Cell. 2019; 176(1-2):11-42. PMC: 6347410. DOI: 10.1016/j.cell.2018.09.048. View

10.

Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D . Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One. 2011; 5(12):e15573. PMC: 3013113. DOI: 10.1371/journal.pone.0015573. View

11.

Parikh A . Lung Cancer Genomics. Acta Med Acad. 2019; 48(1):78-83. DOI: 10.5644/ama2006-124.244. View

12.

Su Y, Wang M, Brenner D, Ng A, Melkonyan H, Umansky S . Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn. 2004; 6(2):101-7. PMC: 1867475. DOI: 10.1016/S1525-1578(10)60497-7. View

13.

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

14.

Li B, Janku F, Jung B, Hou C, Madwani K, Alden R . Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Ann Oncol. 2019; 30(4):597-603. PMC: 6503621. DOI: 10.1093/annonc/mdz046. View

15.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

16.

Tu W, Sun G, Fan L, Wang Y, Xia Y, Guan Y . Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. Lung Cancer. 2019; 132:28-35. DOI: 10.1016/j.lungcan.2019.03.025. View

17.

Selamat S, Galler J, Joshi A, Fyfe M, Campan M, Siegmund K . DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One. 2011; 6(6):e21443. PMC: 3121768. DOI: 10.1371/journal.pone.0021443. View

18.

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

19.

Krug A, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A . Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann Oncol. 2017; 29(3):700-706. PMC: 5889041. DOI: 10.1093/annonc/mdx765. View

20.

Anker P, Stroun M, Maurice P . Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res. 1975; 35(9):2375-82. View